Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

De deal kwam voort uit een competitief biedingsproces tussen TTAM en Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), waarbij het bod van TTAM het eerdere bod van Regeneron van $ 256 mln. overtrof. De ...

Privacy and information commissioners from Canada and the U.K. will reveal the findings of their investigation into the 23andMe data breach.

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...